Toptal is the world’s largest fully remote workforce, powered by a global network of more than 20,000 highly vetted professionals in AI, technology, design, finance, marketing, and strategic consulting. Only the top 3% of applicants are accepted into our network. Founded in 2010, Toptal has been trusted by more than 25,000 clients, from the Fortune 500 to cutting-edge startups. We provide a variety of services to drive businesses forward, from on-demand talent and teams to complete end-to-end solutions. | Recently ranked the #1 Most Reliable Professional Services Company in America by Newsweek, Toptal is the world’s largest fully remote workforce, powered by a global network of more than 20,000 highly vetted professionals in AI, technology, design, finance, marketing, and strategic consulting. Only the top 3% of applicants are accepted into our network. Founded in 2010, Toptal has been trusted by more than 25,000 clients, from the Fortune 500 to cutting-edge startups. We provide a variety of services to drive businesses forward, from on-demand talent and teams to complete end-to-end solutions. | Toptal is the world’s largest fully remote workforce, powered by a global network of more than 20,000 highly vetted professionals in technology, design, finance, marketing, and strategic consulting. Only the top 3% of applicants are accepted into our network. Founded in 2010, Toptal has been trusted by more than 25,000 clients, from the Fortune 500 to cutting-edge startups. We provide a variety of services to drive businesses forward, from on-demand talent and teams to complete end-to-end solutions.
TLC BioSciences
TLC BioSciences is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®). TLC’s deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX® active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC was consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations every year until the company went private in 2021. | TLC BioSciences is a late clinical stage specialty pharmaceutical company. At TLC, we are dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC is dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC BioSciences is a clinical‑stage biotechnology company advancing lipid‑engineered medicines across metabolic, orthopedic, and immune‑cell therapy. Our proprietary LipAD® family of platforms—including BioSeizer® sustained‑release technology, NanoX® active drug‑loading systems, and next‑generation targeted lipid nanoparticles (tLNP)—enables long‑acting, targeted, and programmable delivery for a wide range of therapeutic modalities. With a robust pipeline spanning once‑monthly GLP‑1 therapy (TLC518), late‑stage non‑opioid pain programs, and in‑vivo CAR‑T applications, TLC is committed to delivering medicines with improved efficacy, safety, and accessibility.
TIMS Medical, A Division of Foresight Imaging
TIMS Medical offers innovative medical imaging solutions for hospitals and healthcare providers. Our products increase productivity, foster real-time collaboration, and improve connectivity between medical devices and imaging archives.
Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 2,800 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives. | Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are committed to moving our customers through their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 100 subsidiaries and 180 service locations, with over 10,000 employees across 54 countries in Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables boundless possibility for healthcare industry, embracing challenges to fulfill our commitment to serve unmet patients’ needs, and eventually saving lives. | Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,200 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.
The Woodlands Area Economic Development Partnership
The Woodlands Area EDP is a public-private partnership that leads economic development for the are around The Woodlands, Texas. The Woodlands is a biomanufacturing hub with substantial activity in small molecules and the therapeutics value chain. It is home to life sciences companies including Bionova, Cellipont, Nurix, VGXI, Rigaku Americas, Lexicon Pharmaceuticals, and MilliporeSigma, in addition to a 12-acre life science campus developed and managed by Alexandria Real Estate Equities. Recently named the #2 Best City to Live in America by Niche, The Woodlands provides excellent quality of life in a luxury employment center with access to the tremendous assets available in the Houston metro.
The Medicine Accelerator
The Medicine Accelerator (TMA) is a privately owned, science driven, diverse modality CDMO partner that specializes in bioprocess engineering, process development and GMP manufacturing to create scale-up strategies for effective and fully portable tech transfer and manufacturing control for CGT, vaccines, peptides, ATMPs, small and large molecules. TMA’s proprietary, first in class, iAchieve® cloud-based knowledge management platform tracks and curates data in real-time and provides visibility to every CMC decision made during a molecule’s journey. APC is a team of 300 strong with a 14-year track record of large pharma and biotech partnerships demonstrating significant process, recovery, timeline, and COGs improvements for mammalian, human, and microbial systems. Construction is ongoing to double our footprint and staff in 2026.